Table 2.
Syncope: Pacing or Recording in the Later Years (SPRITELY) trial participant characteristics at baseline in economic evaluation
| Characteristics | Empiric PM insertion (n = 56) | ICM (n = 57) |
|---|---|---|
| Age, y (mean (SD) | 74.5 (9.3) | 77.4 (8.5) |
| Sex, female | 19 (33.9) | 14 (24.6) |
| Comorbidities | ||
| Diabetes | 12 (21.4) | 18 (31.6) |
| Atrial fibrillation | 1 (1.8) | 3 (5.3) |
| Supraventricular tachycardia | 1 (1.8) | 1 (1.8) |
| Ventricular tachycardia | 1 (1.8) | 0 (0) |
| Medications | ||
| Calcium-channel blockers | 16 (28.6) | 20 (35.1) |
| Beta-blockers | 17 (30.4) | 17 (29.8) |
| Alpha 1 antagonists | 1 (1.8) | 7 (12.3) |
| Angiotensin receptor blockers | 18 (32.1) | 9 (15.8) |
| Angiotensin-converting enzyme inhibitors | 16 (28.6) | 20 (35.1) |
| Diuretics | 20 (35.7) | 16 (28.1) |
| Nitrates | 5 (8.9) | 5 (8.8) |
| LVEF, mean (SD) | 59.9 (7.7) | 58.1 (8.0) |
| Lifetime syncopal spells, mean (SD) | 4.5 (5.3) | 4.3 (7.3) |
Values are n (%), unless otherwise indicated.
ICM, implantable cardiac monitor; LVEF, left ventricular ejection fraction; PM, pacemaker; SD, standard deviation.